# Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)

> **NCT04760743** · PHASE1 · COMPLETED · sponsor: **SK Bioscience Co., Ltd.** · enrollment: 50 (actual)

## Conditions studied

- COVID-19 (Healthy Volunteers)

## Interventions

- **BIOLOGICAL:** NBP2001 adjuvanted with alum (RBD 30μg/dose)
- **BIOLOGICAL:** NBP2001 adjuvanted with alum (RBD 50μg/dose)
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04760743
- **Lead sponsor:** SK Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2021-04-02
- **Final completion:** 2022-03-02
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04760743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04760743, "Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04760743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*